Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient ...
Agios Pharmaceuticals Inc. AGIO stock is trading lower after the update on the sickle cell disease program. The company ...
The biotech firm said it will discontinue development of its therapy for sickle cell disease following the outcome of a Phase ...
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s ...
A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued ...
Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results